STAMFORD, Conn., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq: LOXO ), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced that the company will be participating in the following upcoming investor conferences:
- At the Citi Annual Biotech Conference on September 8, 2016 at 8:00AM ET in Boston, Joshua H. Bilenker , M.D., chief executive officer, will be participating in a panel discussion entitled, “Developing Cancer Therapeutics in 2016”
- At the Morgan Stanley Global Healthcare Conference on September 14, 2016 at 2:10PM ET in New York City, Joshua H. Bilenker, M.D., chief executive officer, will present a corporate overview
Live webcasts of the panel and presentation will be available at http://ir.loxooncology.com/ .
About Loxo Oncology Loxo Oncology is a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers. Our pipeline focuses on cancers that are uniquely dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect. We believe that the most selective, purpose-built medicines have the highest probability of maximally inhibiting the intended target, thereby delivering best-in-class disease control and safety. Our management team seeks out experienced industry partners, world-class scientific advisors and innovative clinical-regulatory approaches to deliver new cancer therapies to patients as quickly and efficiently as possible. For more information, please visit the company's website at www.loxooncology.com .
Contacts for Loxo Oncology, Inc.
Company: Jacob S. Van Naarden Chief Business Officer jake@loxooncology.com
Investors: Peter Rahmer The Trout Group, LLC 646-378-2973 prahmer@troutgroup.com
Media: Dan Budwick Pure Communications, Inc. 973-271-6085 dan@purecommunicationsinc.com